This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week
double-blind treatment phase, followed by a 2 week single-blind follow-up
hydrochlorothiazide treatment phase. The combined total duration of patient participation
is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in
size (98) will comprise the study population: placebo or various alagebrium dose groups (10,
50, or 150 mg/day).
- Men or women at least 45 years of age with uncontrolled systolic hypertension
measured by office cuff and by an ambulatory blood pressure monitoring device
- Willingness to be taken off any current antihypertensive treatment to be placed on
hydrochlorothiazide in combination with study medication.
- Any significant history, systemic illnesses, or medical condition(s) that could lead
to difficulty complying with the protocol or that could confound interpretation of
Milan Kovacevic, MD, PhD
Synvista Therapeutics, Inc